    |
||||||||||
 |
||||||||||
 |
||||||||||
News CryoCath Technologies Notice of Annual MeetingMontreal, February 20, 2008 - CryoCath® Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced details for its annual meeting, hosted by Jan Keltjens, President & CEO.
About Medtronic CryoCathCryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias. This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section. For further information, please contact:
|
||||||||||
|
||||||||||
